Stocchi, Fabrizio http://orcid.org/0000-0002-5763-0033
Angelo Antonini, http://orcid.org/0000-0003-1040-2807
Barone, Paolo
Bellelli, Giuseppe
Fagiolini, Andrea
Ferini Strambi, Luigi
Sorbi, Sandro
Padovani, Alessandro
Funding for this research was provided by:
Lundbeck Italia
Article History
Received: 18 November 2022
Accepted: 5 March 2023
First Online: 27 April 2023
Declarations
:
: Our manuscript does not report on or involve the use of any animal or human data or tissue and does not contain data from any individual person, so this section is not applicable to our submission.
: F. B. has received compensation for consultancy and speaker related activities from Zambon, UCB, Chiesi Pharma, Lundbeck, Sunovion, Bial, SynAgile, Biogen, Kiowa, and Impax. A. A. has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche, and Medscape; he receives research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020 Grant 825785, Horizon 2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, and Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling. A. F. is/has been a consultant and/or a speaker and/or has received research grants from Angelini, Apsen, Boheringer Ingelheim, Lundbeck, Janssen, Viatris, Otsuka, Recordati, Sanofi-Aventis, and Sunovion. LFS has received speaker fees from Jazz Pharma, Lundbeck, Angelini, Valeas, Bioprojet, Fidia, and Idorsia and has served on scientific advisory boards for Jazz Pharma, Italfarmaco, Bioprojet, Bayer, and Idorsia. C. M. received funds from the following companies: Novo-nordisk, Angelini, Lundbeck, Roche, and Biogen as consultant in scientific board and congress speaker. P. B., G. B., S. S., and A. P. declare no competing interests.